Biofarm, (stock symbol BIO), one of the most important drug manufacturers in Romania, ended 2023 with a net profit of about 77 million lei, up 9% from the previous year and a turnover of approx. 280 million lei, according to preliminary results (unaudited).
"In 2023, we successfully implemented cost optimization strategies, focusing in particular on two of our company values: performance and end-consumer care. In doing so, we were able to identify effective ways to control our expenses, even in the context of rising raw material and packaging prices. The Consumer Healthcare category in Romania is becoming more and more competitive year by year, marked also by a slight decline in volumes in 2023 compared to 2022. However, we ended 2023 managing to consolidate our position on the market, with a positive evolution of the volume market share and to contribute positively on the quality of life of patients and consumers in Romania", said Cătălin Vicol, Biofarm CEO.
Biofarm continued to strengthen its market share in the Consumer Healthcare (CHC) segment, and ended 2023 in second position in terms of number of units sold.
The company dominates in value in 6 key categories across brands: Bixtonim, Triferment, Colebil, Extravalerianic, Carmol and Carbocit. In addition, Biofarm is the volume leader in no less than 8 categories, highlighting the outstanding performance of the brands Bixtonim, Colebil, Triferment, Sennalax, Extravalerianic, Carmol, Carbocit and Nervocalmin. These results confirm the success of Biofarm's approach and commitment to innovation. Through its achievements, the company continues to establish itself as a trusted player in Consumer Healthcare, offering effective and affordable solutions to consumers.
Biofarm has two drug factories in Bucharest and a product testing and development unit, and its portfolio of over 100 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system). Constant innovation in the development of new products is one of the fundamental elements for Biofarm's expansion and strengthening its position among the leaders in the pharmaceutical industry.
The information provided by KomuniK
Romanian author Mircea Cărtărescu is on the longlist for this year’s International Booker Prize, the influential award for translated fiction, with the novel Solenoid, translated into English by Sean Cotter and published at Pushkin Press. He is the first Romanian author to be longlisted for the prize, alongside 12 other authors nominated for the International Booker […]
Investors from Western Europe, particularly Austria, the Netherlands, Belgium, and the United Kingdom, have been the most active buyers of real estate assets in Romania over the past five years (2019–2024), making investments totaling EUR 1.75 billion, according to data from real estate consultancy Cushman & Wakefield Echinox. The Western European's market share accounted for […]
On Tuesday, February 25, the Bucharest Stock Exchange (BVB) granted 20 awards to listed companies, brokerage companies, as well as to private pension and investment funds for their achievements in 2024 as part of the 12th edition of the BVB Awards. In the opening speeches, stock exchange officials also highlighted the growth of the local […]
Romanian football club FCSB announced on Tuesday, February 25, that its website has been targeted by a Distributed Denial of Service (DDoS) attack, which has caused disruptions in the online ticketing process. The incident occurred as the Bucharest team was selling tickets for the match against Olympique Lyon in the Europa League round of 16. […]
The training program in sustainable development runs from April to July 2025, in 5 development regions of Romania. The postgraduate course targets over 1,200 future experts in sustainable development, who will become local leaders of change. The total value of the training program is RON 5.3 million, with funding entirely sourced from the National Recovery […]
A new report from Colliers highlights significant trends in Romania's housing market for 2025, revealing a continued rise in home prices, limited new supply, and increased demand for rental properties. The findings show that while housing deliveries fell by 15% nationwide and over 20% in Bucharest, demand increased by 7% in 2024. As a result, […]
